Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Effient Prasugrel hydrochloride Acute Coronary Syndrome Do not list Complete
Effient Prasugrel Acute coronary syndrome Do not list Complete
Egrifta Tesamorelin Lipodystrophy, HIV-infected patients Do not reimburse Complete
Elaprase Idursulfase Mucopolysarccharidosis II (MPS II), Hunter Syndrome Do not list Complete
Elelyso Taliglucerase alfa Gaucher disease Do not list Complete
Eliquis Apixaban Venous thromboembolic events, treatment and prevention of recurrence List with clinical criteria and/or conditions Complete
Eliquis Apixaban Venous thromboembolic events, prevention List with clinical criteria and/or conditions Complete
Eliquis Apixaban Thromboembolic events prevention, (atrial fibrillation) List with clinical criteria and/or conditions Complete
Elrexfio elranatamab Relapsed or refractory multiple myeloma Reimburse with clinical criteria and/or conditions Active
Emend Aprepitant Nausea and Vomiting, Chemotherapy induced List with clinical criteria and/or conditions Complete
Emgality galcanezumab Episodic cluster headache Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Emgality galcanezumab Prevention of migraine Reimburse with clinical criteria and/or conditions Complete
Empaveli pegcetacoplan Paroxysmal nocturnal hemoglobinuria Reimburse with clinical criteria and/or conditions Complete
Enablex Darifenacin hydrobromide Bladder, overactive Do not list Complete
Enablex Darifenacin hydrobromide Bladder, overactive List with clinical criteria and/or conditions Complete
Enerzair Breezhaler indacaterol glycopyrronium mometasone furoate Asthma maintenance, adults Reimburse with clinical criteria and/or conditions Complete
Enhertu trastuzumab deruxtecan Metastatic HER2 positive breast cancer Reimburse with clinical criteria and/or conditions Complete
Enhertu trastuzumab deruxtecan Metastatic HER2-positive breast cancer Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Enhertu trastuzumab deruxtecan Gastric or gastroesophageal junction (GEJ) adenocarcinoma Received
Enhertu trastuzumab deruxtecan unresectable or metastatic HER2-low breast cancer Reimburse with clinical criteria and/or conditions Complete
Enspryng satralizumab Neuromyelitis optica spectrum disorder Reimburse with clinical criteria and/or conditions Complete
Entresto sacubitril/valsartan Heart failure, NYHA Class II or III Reimburse with clinical criteria and/or conditions Complete
Entresto Sacubitril/valsartan Heart failure, NYHA class II or III List with clinical criteria and/or conditions Complete
Entuzity KwikPen human insulin Diabetes mellitus Reimburse with clinical criteria and/or conditions Complete
Entyvio vedolizumab Crohn’s disease Reimburse with clinical criteria and/or conditions Complete